Apr 20, 2000|
Pharma funds - Tonic for ailing investors?
Nothing seems to be coming in the markets way on its south-bound journey. Even the NASDAQ, which recovered over the past two days did not mirror a rise in the local markets. With all stocks falling like nine-pins, investors could take a closer look at pharma stocks.
There is no denying the fact that the sharp decline in the markets since the last week has been pervasive taking all sectors in its wake. But there is also no denying that software stocks have been hit the hardest. Nervousness on the NASDAQ has played its own role in pulling down software stocks. Earlier equitymaster.com had advised investors to wait patiently (as far as software funds are concerned) till the dust settles down (which could take a while).
Looking around, one realises that pharma stocks have not been hammered as badly as software. Whatever selling one has seen in pharma stocks has been largely due to redemption pressure on fund managers and due to the negative sentiment prevailing in the markets that has pulled down just about everything. The table below shows the performance of pharma funds over the past 5 days.
||NAV (Rs) as on
|Kothari Pioneer Pharma Fund (Div)
|Kothari Pioneer Pharma Fund (Gr.)
|Magnum Pharma Fund
|UTI Pharma & Healthcare Fund
While pharma funds have also fallen (like other sectoral funds) there is much merit in buying into pharma funds at current levels. Unlike software stocks, valuations of pharma stocks are more realistic. Pharma stocks are also immune from the strong undercurrents in the US markets, which gives Indian software stocks a cold every time the NASDAQ sneezes. In other words, pharma stocks are bound to reflect the performance of pharma companies more clearly as opposed to software stocks, which seem to be on their trip at present. And of course for the value investor, pharma funds are really cheap now.
More Views on News
Mar 10, 2016
An opportunity to find an impeccably trustworthy and competent financial guardian is in the offing.
Feb 29, 2016
Most financial planners come out as whiz kids who throw around financial jargon. But financial planning can be actually easy, provided one follows a disciplined approach.
Feb 12, 2016
PersonalFN highlights the benefits of parking a portion of your expenses in e-wallets and using them efficiently.
Feb 2, 2016
Mutual funds take a bearish call on the FMCG sector. The sector has started playing out due to a combination of slower growth and expensive valuations.
Feb 1, 2016
Ethical practices help build long lasting relationships, and healthy long-term business relationships are often mutually rewarding. But PersonalFN is of the view that the financial services industry in India seems to have forgotten this.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407